TScan is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.
Within the tumors of cancer patients are T cells with the ability to recognize and eliminate cancer cells. We are using our proprietary target ID platform to identify the natural targets of tumor-reactive T cells and identify therapeutically active TCRs that are both safe and effective.
TScan’s experienced leadership team shares the goal of delivering groundbreaking cancer treatments to patients.
For more information about TScan, career or collaboration opportunities.
Scientific Co-founder of TScan
Dana-Farber Cancer Institute
Houston Methodist Hospital
Professor Emeritus, Medicine, Harvard Medical School
Assistant Professor of Pathology, Johns Hopkins Medicine